BioTech SXTC

Why SXTC Shares Surge?

(RTTNews) - China SXT Pharmaceutics, Inc. (SXTC) shares are surging above 50%. Despite, no corporate updates on Monday, the sudden change is closely watched by investors. On last Friday, China SXT had announced a massive share consolidation of 1-for-150 of its ordinary shares, effective on February 3, 2026.

China SXT is a pharmaceutical company that engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine products or TCMP in China.

Upon the market opening on February 3, 2026, the Company's Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol "SXTC" with the new CUSIP number G2161P165.

Prior to the Share Consolidation, 143.69 million Class A ordinary shares were issued and outstanding, and as a result of the share consolidation, every 150 shares will be combined into one, and approximately 0.96 million Class A ordinary shares will be issued and outstanding after the share consolidation.

The Company is authorized to issue an unlimited number of shares, divided into two Classes consisting of Class A ordinary shares with no par value and Class B ordinary shares with no par value.

Over the year SXTC traded between $0.027 and $6.98. The stock closed Friday's trade at $0.031.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available